Roivant Sciences (NASDAQ: ROIV) revenue
Roivant Sciences reported revenue of $8.3m for fiscal 2026, 71.6% less than in fiscal 2025 ($29.1m). Since fiscal 2021 its revenue has fallen by 65.3%, an average decline of 19.1% a year.
Roivant Sciences's revenue has fallen for 2 years in a row, and its best year of the last 6 was fiscal 2022. The biggest drop was in fiscal 2026, −71.6%.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Revenue by fiscal year
| Fiscal year | Revenue | Change | Operating profit | Operating margin |
|---|---|---|---|---|
| 2026 | $8.3m | −71.6% | −$515.1m | −6,235.7% |
| 2025 | $29.1m | −11.2% | −$1,003m | −3,453.3% |
| 2024 | $32.7m | +3.8% | $4,497m | 13,746.9% |
| 2023 | $31.5m | −43.0% | −$906.8m | −2,875.9% |
| 2022 | $55.3m | +132.3% | −$1,352m | −2,444.8% |
| 2021 | $23.8m | — | −$1,071m | −4,500.5% |
The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Roivant Sciences revenue compared with its sector
By revenue for its latest fiscal year, Roivant Sciences ranks 373rd of the 422 US health care companies with a page on Celsmar. The sector median grew 11.7% in its latest fiscal year; Roivant Sciences, −71.6%.
| Rank | Company | Revenue | Revenue growth |
|---|---|---|---|
| 371st | Prothena Corporation Public | $9.7m | −92.8% |
| 372nd | Bioage Labs | $9.0m | — |
| 373rd | Roivant Sciences | $8.3m | −71.6% |
| 374th | Aclaris Therapeutics | $7.8m | −58.2% |
| 375th | Xenon Pharmaceuticals | $7.5m | — |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the revenue of Roivant Sciences
- How much revenue did Roivant Sciences make in fiscal 2026?
- Roivant Sciences reported revenue of $8.3m for fiscal 2026, compared with $29.1m in fiscal 2025.
- How much has the revenue of Roivant Sciences fallen?
- Between fiscal 2021 and fiscal 2026 it went from $23.8m to $8.3m: 65.3% less, an average decline of 19.1% a year.
- What was the best year for revenue at Roivant Sciences?
- Of its last 6 fiscal years, fiscal 2022, with $55.3m.
- Where does Roivant Sciences rank in its sector by revenue?
- It ranks 373rd of the 422 US health care companies with a page on Celsmar, by revenue for its latest fiscal year.
- Where do the figures for Roivant Sciences come from?
- From the annual report (Form 10-K) that Roivant Sciences files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Roivant Sciences files with the SEC. The filing for each fiscal year: 2026 · 2025 · 2024 · 2023 · 2022 · 2021. More on Roivant Sciences: the Roivant Sciences page · annual accounts · net income · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.